Latham & Watkins Advises Ascendis Pharma A/S in US$500 Million Convertible Notes Offering

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, has announced the pricing of its offering of US$500,000,000 aggregate principal amount of 2.25% convertible senior notes due 2028 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The issuance and sale of the notes are scheduled to settle on March 29, 2022, subject to the satisfaction of customary closing conditions. Ascendis Pharma also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$75,000,000 aggregate principal amount of notes.

Latham & Watkins LLP represents Ascendis Pharma A/S in the offering with a corporate deal team led by Bay Area partners Mark Roeder and John Williams, with Bay Area associates Tess Bloom, Zuzanna Gruca, and Tyler Israel and New York associate Lia-Michelle Keane. Advice was also provided on equity-linked matters by Los Angeles/New York partner Greg Rodgers, Los Angeles partner Arash Aminian Baghai and New York partner Reza Mojtabaee-Zamani, with New York associates Ryan Gold and Christopher Yu; on tax matters by New York partner Elena Romanova, with New York associate Michael Syku; on intellectual property matters by Bay Area partner Judith Hasko, with Los Angeles associate Michael Sweeney; on regulatory matters by Washington, D.C. partner Ben Haas, Paris/Brussels partner Eveline Van Keymeulen, and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings and San Diego associate Kiera Murphy; on data privacy matters by Bay Area partner Heather Deixler; and on benefits and compensation matters by Bay Area partner James Metz.